Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues.

Jensen AM, Brocks V, Holm K, Laursen EM, Müller J

The Journal of pediatrics1 Jan 1998Cited by 36 (Europe PMC)

PMID9470009DOI10.1016/s0022-3476(98)70493-7PepBankPUB-09470009

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In girls with central precocious puberty, ovarian volume decreased significantly to age-normal values during Decapeptyl treatment.
In plain wordsIn girls with early puberty, ovarian volume decreased to normal values for age during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseOvarian volume during treatment
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeks · 3 monthsAs given in this study (human).
Measurements
Median ovarian volume
1.1 SD
at diagnosis
Median ovarian volume
0 SD
after 3 months
Source sentences
Summary
Within 3 months of treatment, both ovarian and uterine volumes decreased significantly (p < 0.01) to normal values appropriate for age.
Summary
Median ovarian volume at time of diagnosis was 1.1 standard deviation scores (range -0.6 to 3.2 SD), median uterine volume was 1.8 standard deviation scores (range 0.0 to 3.5 SD).
3 context sentences(design, population, supporting numbers)
Summary · context
Median ovarian volume after 3 months of treatment was 0.0 SD (range -2.4 to 1.5 SD); median uterine volume was 0.7 SD (range -0.6 to 4.1 SD).
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000901
02HumanObservational studyEfficacy outcome
In girls with central precocious puberty, uterine volume decreased significantly to age-normal values during Decapeptyl treatment.
In plain wordsIn girls with early puberty, uterine volume decreased to normal values for age during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterine volume during treatment
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeks · 3 monthsAs given in this study (human).
Measurements
Median uterine volume
1.8 SD
at diagnosis
Median uterine volume
0.7 SD
after 3 months
Source sentences
Summary
Within 3 months of treatment, both ovarian and uterine volumes decreased significantly (p < 0.01) to normal values appropriate for age.
Summary
Median ovarian volume at time of diagnosis was 1.1 standard deviation scores (range -0.6 to 3.2 SD), median uterine volume was 1.8 standard deviation scores (range 0.0 to 3.5 SD).
3 context sentences(design, population, supporting numbers)
Summary · context
Median ovarian volume after 3 months of treatment was 0.0 SD (range -2.4 to 1.5 SD); median uterine volume was 0.7 SD (range -0.6 to 4.1 SD).
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000902
03HumanObservational studyEfficacy outcome
In girls with central precocious puberty, ovarian volume remained within the normal range after Decapeptyl discontinuation.
In plain wordsIn girls with early puberty, ovarian volume remained normal after Decapeptyl stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOvarian volume after discontinuation
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeksAs given in this study (human).
Source sentences
Summary
Ovarian and uterine volume remained within normal range (< 2 standard deviation scores) after discontinuation of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000903
04HumanObservational studyEfficacy outcome
In girls with central precocious puberty, uterine volume remained within the normal range after Decapeptyl discontinuation.
In plain wordsIn girls with early puberty, uterine volume remained normal after Decapeptyl stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableUterine volume after discontinuation
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeksAs given in this study (human).
Source sentences
Summary
Ovarian and uterine volume remained within normal range (< 2 standard deviation scores) after discontinuation of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000904
05HumanObservational studyEfficacy outcome
In girls with central precocious puberty, follicles regressed during Decapeptyl treatment.
In plain wordsIn girls with early puberty, ovarian follicles regressed during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFollicle regression
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeksAs given in this study (human).
Source sentences
Summary
Follicles and macrocysts regressed during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000905
06HumanObservational studyEfficacy outcome
In girls with central precocious puberty, macrocysts regressed during Decapeptyl treatment.
In plain wordsIn girls with early puberty, large ovarian cysts regressed during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMacrocyst regression
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeksAs given in this study (human).
Source sentences
Summary
Follicles and macrocysts regressed during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000906
07HumanObservational studySafety outcome
In girls with central precocious puberty, no polycystic ovarian appearance occurred during or after Decapeptyl treatment.
In plain wordsIn girls with early puberty, no ovaries appeared polycystic during or after Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePolycystic ovarian appearance
Study
n = 33
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
75 micrograms/kg every 4 weeksAs given in this study (human).
Source sentences
Summary
None of the girls' ovaries had a polycystic appearance during or after treatment with the gonadotropin-releasing hormone analogue.
2 context sentences(design, population, supporting numbers)
Summary · context
Pelvic ultrasonography was systematically performed on 33 girls with idiopathic central precocious puberty to investigate the impact of treatment with gonadotropin-releasing hormone analogues on female internal genitalia.
Summary · context
All girls were treated with a long-acting gonadotropin-releasing hormone analogue (Decapeptyl Depot; Ferring Co., Copenhagen, Denmark) 75 micrograms/kg every 4 weeks.
Report a problemFND-0947000907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.